RxDoctor Payments Data

Kristin Hammersmith, MD

Ophthalmology · Philadelphia, PANPI 1437157187

Payments from drug & device makers

$14,193in general payments, 2019–2025

Across 109 payments — averaging $130.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$10K
  • Dompe US, Inc.$2K
  • Shire North American Group Inc$714
  • Biotissue Holdings Inc.$510
  • Sun Pharmaceutical Industries Inc.$369
  • Novartis$185
  • plus $909 from 10 others

What the payments were for

  • Consulting fees$8,57560%
  • Speaking & faculty fees$1,77012%
  • Travel & lodging$1,44010%
  • Food & beverage$2,38917%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,193 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$148,369
Medicare patients
441
Services billed
1,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj24$675,463
RestasisCyclosporine143$212,451
Cyclosporine96$66,045
XiidraLifitegrast37$63,066
Prednisolone Acetate535$25,337
Loteprednol Etabonate76$16,884
TyrvayaVarenicline Tartrate17$11,926
LotemaxLoteprednol Etabonate23$9,497
ZirganGanciclovir15$9,330
CequaCyclosporine12$8,909
Brimonidine Tartrate82$7,980
ErythromycinErythromycin Base611$7,857
CombiganBrimonidine Tartrate/Timolol31$7,754
Fluorometholone82$7,249
Doxycycline Hyclate156$7,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$1,839$675,46324 claims
AbbVieRestasis, Combigan$181$220,206174 claims
Bausch & Lomb Americas Inc.Xiidra, Zirgan$17$72,39652 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax$93$26,38199 claims
Oyster Point Pharma, Inc.Tyrvaya$148$11,92617 claims
Sun Pharmaceutical Industries Inc.Cequa$369$8,90912 claims
Eyevance Pharmaceuticals LLCFlarex$91$6,66740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →